

# PI3K inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/P8326A7C1A0EN.html>

Date: January 2022

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: P8326A7C1A0EN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "PI3K inhibitors- Pipeline Insight, 2022" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### PI3K inhibitors Understanding

#### PI3K inhibitors: Overview

Phosphatidylinositol-3 kinases (PI3Ks) are lipid kinases that phosphorylate signaling lipid PIP2 to PIP3. PIP3 molecules recruit proteins bearing PIP3-binding pleckstrin homology (PH) domains such as Akt in the PI3K/Akt/mTOR signaling pathway to the plasma membrane. The PI3K pathway is among the most frequently activated in human cancers, impacting almost 50% of the malignancies. Class IA isoforms PI3K $\alpha$ ,  $\beta$  and  $\gamma$  are particularly strongly associated with cancer. Activating mutations in the PIK3CA gene, which encodes the p110 $\alpha$  catalytic subunit of PI3K $\alpha$  and suppressing mutations of tumor suppressor PTEN<sup>5,6</sup> (a lipid phosphatase that dephosphorylates PIP3, thus opposes PI3K $\alpha$  action) are the second and third most frequently mutated in cancer, making PI3K $\alpha$  a vastly important target for drug discovery

## PI3K inhibitors Emerging Drugs Chapters

This segment of the PI3K inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### PI3K inhibitors Emerging Drugs

#### Umbralisib: TG Therapeutics

Umbralisib (TGR-1202) is an oral, once daily, dual inhibitor of PI3K delta and CK1 epsilon. Umbralisib has nanomolar potency to the delta isoform of PI3K and high selectivity over the alpha, beta, and gamma PI3K isoforms. Umbralisib also uniquely inhibits casein kinase 1 epsilon (CK1 epsilon), which may have both direct anti-cancer effects and may also modulate T-cell activity associated with immune-mediated adverse events seen with previous PI3K inhibitors. Currently, umbralisib is being evaluated in Phase IIb and Phase III trials in patients with NHL and CLL.

#### Gedatolisib: Pfizer

Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Pfizer. It works by targeting PI3K/mTOR. The Phase II clinical trials of gedatolisib for treatment of endometrial cancer and colorectal cancer were terminated early due to enrollment issues. It is currently in phase II stage of development.

#### Parsaclisib: Incyte Corporation

Parsaclisib is a potent, highly selective, next-generation PI3K $\gamma$  inhibitor that is not associated with clinically meaningful transaminitis. It is in phase II stage of development.

#### YH 25248: Yuhan

YH 25248 is an oral selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, being developed by Yuhan, for the treatment of cancer.

Further product details are provided in the report.....

### PI3K inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PI3K inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in PI3K inhibitors

There are approx. 100+ key companies which are developing the therapies based on PI3K inhibitors. The companies which have their drug candidate based on PI3K inhibitors in the most advanced stage, i.e. phase II/III include TG Therapeutics and others

#### Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

PI3K inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs

such as

Infusion

Intradermal

Intramuscular

Intranasal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

## PI3K inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PI3K inhibitors therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PI3K inhibitors drugs.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence PI3K inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

In May 2019, Onconova to receive USD 4 Million upfront, including USD 2 Million Fee and USD 2 Million for Onconova Shares Purchased at a Premium, Plus up to USD 45.5 Million in Regulatory and Sales Milestones for Rigosertib in Greater China.

In December 2019, Onconova Therapeutics, and Inceptua Medicines announced that they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.

## PI3K inhibitors Report Insights

PI3K inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

## Impact of Drugs

### PI3K inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

### Key Questions

What are the current treatment options available based on the PI3K inhibitors?

How many companies are developing therapies by working on PI3K inhibitors?

What are the principal therapies developed by these companies in the industry?

How many therapies are developed by each company for PI3K inhibitors to treat disease condition?

How many emerging therapies are in early-stage, mid-stage, and late stage of development for PI3K inhibitors?

Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the PI3K inhibitors therapies?

Which are the dormant and discontinued products and the reasons for the same?

What is the unmet need for current therapies developed based on this mechanism of action?

What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for PI3K inhibitors and their status?

What are the results of the clinical studies and their safety and efficacy?

What are the key designations that have been granted for the emerging therapies for PI3K inhibitors?

How many patents are granted and pending for the emerging therapies of PI3K inhibitors?

## Key Players

TG Therapeutics

Pfizer

Incyte Corporation

Yuhan

Inflection Biosciences/AUM Biosciences

Onconova Therapeutics

UCB

## Key Products

Umbralisib

Gedatolisib

Parsaclisib

YH 25248

Research programme: anti-cancer therapeutics

Rigosertib

Seletalisib



## Contents

Introduction

Executive Summary

PI3K inhibitors: Overview

- Classification
- Mechanism of Action
- Structure
- Application

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

PI3K inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- PI3K inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

PI3K inhibitors Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Umbralisib: TG Therapeutics

- Product Description
- Research and Development
- Product Development Activities

Mid Stage Products (Phase II)

- Comparative Analysis

Gedatolisib: Pfizer

- Product Description
- Research and Development
- Product Development Activities

Parsaclisib: Incyte Corporation

- Product Description
- Research and Development

- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

Drug Name: Company Name

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis

YH 25248: Yuhan

- Product Description

- Research and Development

- Product Development Activities

Inactive Products

- Comparative Analysis

PI3K inhibitors Key Companies

PI3K inhibitors Key Products

PI3K inhibitors- Unmet Needs

PI3K inhibitors- Market Drivers and Barriers

PI3K inhibitors- Future Perspectives and Conclusion

PI3K inhibitors Analyst Views

PI3K inhibitors Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for PI3K inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for PI3K inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: PI3K inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/P8326A7C1A0EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8326A7C1A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970